(2Z)-2-[(4-fluorophenyl)hydrazinylidene]cyclohexan-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2Z)-2-[(4-fluorophenyl)hydrazinylidene]cyclohexan-1-one
• 化学式: C₁₂H₁₃FN₂O
• mdl: MFCD00715520
• 分子量: 220.24
• InChiKey: PQLGJYWEBWNBLE-PTNGSMBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] NOVEL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCÉDÉS POUR LEUR PRÉPARATION
  申请人：MATRIX LAB LTD

  公开号：WO2009115874A2

  公开（公告）日：2009-09-24

  The present invention relates to novel heterocyclic compounds of general formula (I) that are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors. These novel PDEs are useful in the treatment of inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) as well as disorders or conditions generally characterized by or associated with an excessive secretion of TNF-α and Phosphodiesterase 4 (PDE IV).